This scanning electron microscope image shows the T cell-trapping biomaterial up-close with cavities and ducts allowing the entry, as well as movement and binding of autoimmune T cells in its interior. Photo courtesy of James Weaver.
Adapted from a Joslin Diabetes Center press release
Diabetes researchers have puzzled for decades about why insulin-producing beta cells in one pancreatic islet often look and behave quite differently than their counterparts in the same islet or in nearby islets. Using newly identified cellular markers of aging, Joslin Diabetes Center scientists now have shown that this diversity may be driven at least in part by differently aged beta cell populations within the pancreas.
Additionally, the Joslin team demonstrated that the aging of beta cells, with associated losses of
Scientists identify a key barrier to proliferation of inuslin-producing cells
If you become resistant to insulin, a condition that is a precursor to type 2 diabetes, your body tries to compensate by producing more of the “beta” cells in the pancreas that produce the critical hormone. Researchers have long sought to understand why these cells often fail to proliferate in people who go on to develop the disease. Studying both humans and mice, scientists at Joslin Diabetes Center now have pinpointed one key biological mechanism that can prevent
In a flask of clear, pale yellow liquid, 300-400 million beta cells, the insulin-producing cells attacked or defective in diabetics, swirl in a cocktail of cell food and Stage 6 medium. Ten years ago, researchers were still working on protocols to turn stem cells into
The Harvard Stem Cell Institute (HSCI), three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed an unusual collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure
Cambridge, MA, June 16,2016 - The Harvard Stem Cell Institute, three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.
Stem cell-derived, glucose-stimulated, insulin-producing cells (SC-β) are protected inside capsules engineered to be invisible to the host immune system. Photo courtesy of Omid Veiseh and Andrew Bader/Anderson/Langer Laboratory, Koch Institute at MIT
Harvard researchers have created a system using human stem cells to screen for compounds that have the potential to turn white, or “bad,” fat cells into brown, or “good,” fat cells. Pictured are human pluripotent stem cell-derived fat cells. (Photo Credit Tim Ahfeldt/